The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 13, 2022

Filed:

May. 10, 2018
Applicant:

Korea Food Research Institute, Jeollabuk-do, KR;

Inventors:

Sueng Mok Cho, Gyeonggido, KR;

Min Young Um, Seoul, KR;

Min Seok Yoon, Seoul, KR;

Hye Jin Yang, Gyeonggi-do, KR;

Jae Kwang Lee, Seoul, KR;

Jong Hoon Jung, Gyeonggi-do, KR;

Assignee:

KOREA FOOD RESEARCH INSTITUTE, Jeollabuk-do, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/05 (2006.01); A61P 25/20 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01); A61K 31/5025 (2006.01); A61K 31/519 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/05 (2013.01); A61K 9/0056 (2013.01); A61K 31/437 (2013.01); A61K 31/496 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); A61P 25/20 (2018.01);
Abstract

The present invention relates to a pharmaceutical composition and a health functional food composition, which include phloroglucinol active ingredient, for preventing, treating, or ameliorating somnipathy and suppressing intolerance to, alleviating, or ameliorating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor. The pharmaceutical composition and the food composition rapidly and reliably induce and maintain sleep, prevent repeated awakenings, unalter physiological sleep architecture, are particularly devoid of residual sedative effects, which could impair daytime functioning and cognitive performance, and neither cause side effects nor intolerance to a conventional agonist at the benzodiazepine binding site of the GABA-A receptor despite long-term administration. The pharmaceutical composition uses a reduced amount of the agonist, which may increase the amount of sleep but degrade the quality of sleep to cause various side effects, to alleviate side effects of the agonist or suppress tolerance to the agonist resulting from long-term administration.


Find Patent Forward Citations

Loading…